ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0293

Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND

Ronald van Vollenhoven1, Stephen Hall2, Alvin Wells3, Sebastian Meerwein4, Yanna Song5, Jessica Suboticki6 and Roy Fleischmann7, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Emeritus Research and Monash University, Melbourne, Australia, 3Aurora Rheumatology and Immunotherapy Center, Franklin, WI, 4AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Mettawa, IL, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2022

Keywords: clinical trial, Disease-Modifying Antirheumatic Drugs (Dmards), Randomized Trial, Response Criteria, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target for those who cannot achieve REM; patients with prior inadequate response or intolerance to biological DMARD therapy (bDMARD-IR) may belong to this group. The objective of this analysis was to evaluate the sustainability of response to the JAK inhibitor upadacitinib (UPA) over 5 years among bDMARD-IR patients.

Methods: Data are from SELECT-BEYOND, a phase 3 randomized trial of UPA 15 mg or 30 mg once daily (placebo [PBO]-controlled for the first 12 weeks) in patients with RA on background conventional synthetic (cs) DMARDs.1 Patients who completed the week 24 visit could enter a long-term extension of up to a total of 5 years. Initiation, change, or discontinuation of background RA medications, including ≤2 csDMARDs, was permitted starting at week 24 per investigators’ discretion. This post hoc analysis only includes data from patients receiving the approved 15 mg dosage: both those randomized to UPA 15 mg and those who switched from PBO to UPA 15 mg. The proportions of patients who achieved REM (CDAI ≤2.8; SDAI ≤3.3), LDA (CDAI ≤10; SDAI ≤11), and DAS28(CRP) < 2.6/≤3.2 between the first dose of UPA and the end of study were assessed. Sustained response was evaluated using the Kaplan-Meier method and defined as the time from when the response was first achieved while on UPA to the earliest date at which the response was lost at two consecutive visits or discontinuation of study drug due to lack of efficacy. Recapture of response was assessed in patients who lost response at 2 consecutive visits but later regained response. The predictive ability of key baseline and demographic characteristics was determined using Harrell’s concordance-index. All analyses used observed case, with discontinuation of the study drug due to lack of efficacy treated as a loss of response.

Results: In this bDMARD-IR population, 104/229 (45%) and 172/219 (79%) of those receiving UPA 15 mg + background csDMARD(s) achieved CDAI REM or LDA at any point during the 5-year study, respectively. At weeks 12, 24, and 48, 10%/37%, 17%/55%, and 29%/70% of patients achieved CDAI REM/LDA. Through the last follow-up visit, 25%/43% of patients receiving UPA sustained CDAI REM/LDA response (Figure 1). The median duration of response was 48 weeks for CDAI REM and 156 weeks for CDAI LDA. Most patients who had lost CDAI REM or CDAI LDA were able to recapture response by the cutoff date (72% [49/68] recaptured CDAI REM and 73% [61/84] recaptured LDA) (Figure 2). No strong predictors of CDAI REM/LDA were identified. Similar overall results were observed for SDAI REM/LDA and for DAS28(CRP) < 2.6/≤3.2.

Conclusion: Most bDMARD-IR patients achieved CDAI LDA on UPA and around half of those maintained LDA through the end of study. Remission was achieved less frequently and maintained in a quarter of the patients. These data underscore that LDA may be a reasonable treatment target in bDMARD-IR patients and that UPA may help achieve that goal in such patients.

References:
1. Genovese, MC et al. Lancet 2018;391:2513–24.

Supporting image 1

Supporting image 2


Disclosures: R. van Vollenhoven, Bristol Myers Squibb (BMS), GlaxoSmithKline (GSK), UCB, Merck/MSD, Pfizer, Roche, AbbVie, AstraZeneca, Biogen, Galapagos, Janssen, Miltenyi, R-Pharma; S. Hall, AbbVie, Bristol-Myers Squibb (BMS), Lilly, Janssen, UCB, Novartis, Amgen, Gilead, Merck; A. Wells, AbbVie; S. Meerwein, AbbVie; Y. Song, AbbVie; J. Suboticki, AbbVie; R. Fleischmann, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Galvani, GlaxoSmithKlein (GSK), Janssen, Pfizer, Gilead, UCB, Novartis, Arthrosi, AstraZeneca, Flexion, Genentech, Horizon, Selecta, Viela, Vorso, Vyne.

To cite this abstract in AMA style:

van Vollenhoven R, Hall S, Wells A, Meerwein S, Song Y, Suboticki J, Fleischmann R. Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/long-term-sustainability-of-response-to-upadacitinib-among-patients-with-active-rheumatoid-arthritis-refractory-to-biological-disease-modifying-anti-rheumatic-drugs-results-through-5-years-from-selec/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-sustainability-of-response-to-upadacitinib-among-patients-with-active-rheumatoid-arthritis-refractory-to-biological-disease-modifying-anti-rheumatic-drugs-results-through-5-years-from-selec/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology